Board of Directors

Mr. Bohlin has served as a member of our Board of Directors since October 2013. Since 2012, Mr. Bohlin has focused exclusively on service on boards of directors and consulting. From 2010 until his retirement in 2012, he served as Executive Vice President of Constellation Pharmaceuticals, Inc., where he served as a part-time business partner with the Chief Executive Officer. Prior to Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, Inc. from 2006 to 2009, where he played key roles in the overall management of Sirtris, its initial public offering and the sale of the company to GlaxoSmithKline. Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals, Inc., from 1999 through 2008, where he played a key role in the overall management of Syntonix, positioning it for an eventual sale to Biogen Idec. Prior to Syntonix, Mr. Bohlin was Executive Vice President of Genetics Institute, Inc., where he played a key role in overall management, its initial public offering and its sale to American Home Products/Wyeth, and a partner at Arthur Andersen & Co. Mr. Bohlin has served on the board of directors and audit committee of Collegium Pharmaceutical, Inc. since 2015 and served on the board of directors at Tetraphase Pharmaceuticals, Inc. from 2010 until July 2020, when Tetraphase was acquired by La Jolla Pharmaceutical Company. Mr. Bohlin holds a B.S. in Accounting from the University of Illinois.

Mr. Greene has served as a member of our Board of Directors since January 2013 and as our Lead Independent Director since January 2015. Mr. Greene has served as Chief Executive Officer of Sage Therapeutics since December 2020. Mr. Greene served as President of Alnylam Pharmaceuticals, Inc., from 2007 to September 2020, and as its Chief Operating Officer from 2003 to 2016. Prior to his 17 year tenure at Alnylam, Mr. Greene was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful U.S. Food and Drug Administration approval and launch of VELCADE ^®  (bortezomib) in 2003. Prior to joining Millennium in 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com, a healthcare consulting company. Prior to Mediconsult.com, Mr. Greene’s experience included serving as Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck), Vice President, Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and a partner of Andersen Consulting, a consulting company, where he was responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene has served as a member of the board of directors of BCLS Acquisition Corp. since October 2020, as a member of the board of directors of Sage Therapeutics since October 2020 and  as a member of the board of directors of Acorda Therapeutics, Inc., since 2007, where he also serves as a member of its compensation committee. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University’s Fuqua School of Business.

Dr. Mirza has served as a member of our Board of Directors since October 2010. He has also served as a clinical consultant to us since 2010. Dr. Mirza is Chief Oncologist at the Department of Oncology, Rigshopitalet – the Copenhagen University Hospital, Denmark and Medical Director of the Nordic Society of Gynaecological Oncology, or NSGO. Dr. Mirza is both a medical and radiation oncologist, with a primary focus in non-surgical treatment of gynecologic cancers. His key academic goals are to promote clinical research, international trial collaboration and education, and he has broad experience in clinical protocol development, trial conduct and clinical trial regulations. Dr. Mirza is the author of several phase 1, 2 and 3 studies, several of those leading to U.S. Food and Drug Administration and European Medicines Agency registrations. He serves on several Independent Data Safety Monitoring Committees of international studies. He is an invited speaker at several international conferences, such as “Meet the Professor” at American Society of Clinical Oncology and “Presidential Symposium” at European Society for Medical Oncology. He is the senior author of national Danish guidelines for the management of endometrial, cervical, vulvar and non-epithelial ovarian cancers as well as of the NSGO radiotherapy guidelines for cervical and vulvar cancers. He is author of European Guidelines in endometrial and vulvar cancers. His other current appointments include service as ESGO Council Member (European Society of Gynaecological Oncology), Executive Director of GCIG (Gynecologic Cancer InterGroup), Vice-Chairman of the Danish Gynecological Cancer Society, Founding Executive Member of the European Network of Gynecologic Oncology Trials Group, faculty member of the European Society of Medical Oncology and of the International Gynecologic Cancer Society. He also serves on the board of directors of Sera Prognostics, Inc., a private biopharmaceutical company. He has multiple publications in high-impact journals, including the New England Journal of Medicine. He holds a M.D., Diploma in Surgery and Diploma in Clinical Oncology from the Pirogov Moscow State Medical Institute as well as post-graduate education and certification in radiation and medical oncology from the University of Southern Denmark.

Mr. Paulson was appointed President and Chief Executive Officer of Karyopharm in May 2021 and has served as a member of Karyopharm’s Board of Directors since February 2020. He was previously an Executive Vice President of Ipsen Pharmaceuticals, Inc. and Chief Executive Officer of Ipsen North America, a global biopharmaceutical company focused on innovation and specialty care in areas of oncology, neuroscience and rare diseases, from  February 2018 to May 2021. Mr. Paulson previously worked at Amgen for 10 years holding varying leadership positions across Europe and North America, including Vice President and General Manager of Amgen’s U.S. Oncology Business Unit, and prior to that served as the Vice President of Marketing for Amgen’s U.S. Oncology Business, General Manager of Amgen Germany, and General Manager of Amgen Central & Eastern Europe. Prior to Amgen, Mr. Paulson held a number of global leadership positions at Pfizer Inc., including serving as General Manager of Pfizer South Africa and Pfizer Czech Republic. Mr. Paulson also previously held a variety of sales, marketing, and market access roles with increasing seniority at GlaxoWellcome in Canada. He is a member of the board of directors of Bluebirdbio.

Mr. Paulson has an MBA from the University of Toronto, Canada and an undergraduate degree in commerce from the University of Saskatchewan, Canada.

Dr. Honig has served as a member of our Board of Directors since December 2021.  Dr. Honig held various positions at Pfizer, most recently as Senior Vice President and Head of Global Regulatory Affairs and Group Head of Development for China and Japan, overseeing regulatory effectiveness, quality control and compliance. Prior to joining Pfizer, he held senior leadership positions at AstraZeneca, Merck Research Laboratories and the FDA, which includes being the first Director of the Office of Drug Safety in the FDA’s Center for Drug Evaluation and Research (CDER). In addition to his industry and FDA experience, Dr. Honig was the PhRMA representative to the International Conference on Harmonisation (ICH) Steering Committee from 2002 to 2021, is a past President of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) and is currently an associate editor of their flagship journal.

Dr. Honig serves on the Boards of several life science companies and other healthcare organizations, including Sesen Bio (NASDAQ: SESN), Alopexx Enterprises, LLC, the Drug Information Association, the Centre of Regulatory Excellence and the Accelerating Therapeutics for Opportunities in Medicine Consortium. He also serves in the Scientific Advisory Board of Travecta Therapeutics. Dr. Honig received his BA, MD and MPH from Columbia University.

Ms. Oliger has served as a member of our Board of Directors since August 2020.  Ms. Oliger was most recently Senior Vice President of the Oncology Business Unit at Genentech, a biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. Ms. Oliger spent two decades with Genentech, holding a number of leadership roles including Senior Vice President, IMPACT Business Unit; Vice President, Pharma Portfolio Management; Vice President, Portfolio Planning and Vice President, Hematology Marketing and Sales. Prior to Genentech, Ms. Oliger held management positions at Schering-Plough. Ms.Oliger holds a bachelor’s degree in Economics from the University of California at Santa Barbara.

Dr. Pakianathan has served as a member of our Board of Directors since April 2013. Since 2001, Dr. Pakianathan has been a Managing Member at Delphi Ventures, a venture capital firm focused on biotechnology and medical device investments and leads the firm’s biotechnology investment activities. From 1998 to 2001, Dr. Pakianathan was a senior biotechnology banker at JPMorgan, a global investment bank, from 1997 to 1998, she was a Research analyst covering biotech at Genesis Merchant Group and from 1993 to 1997 she was a post-doctoral research scientist at Genentech. Dr. Pakianathan has served on the board of directors of Mereo Biopharma Group PLC, since April 2019, where she also serves as a member of its remuneration committee and Calithera Biosciences, Inc., since 2012, where she also serves as the lead independent director and Chair of the compensation committee and the nominating and governance committee. In July 2020, Dr. Pakianathan was also appointed to the board of directors at Theravance Biopharma, Inc. From 2004 to 2016, Dr. Pakianathan served on the board of directors of Alexza Pharmaceuticals, Inc., from 2009 to 2013, Dr. Pakianathan served on the board of directors of PTC Therapeutics, Inc., and from 2007 to 2012, Dr. Pakianathan served on the board of directors of Relypsa, Inc.. Dr. Pakianathan holds a M.S. and Ph.D. from Wake Forest University, a B.Sc. from the University of Bombay, India, and a M.Sc. from The Cancer Research Institute at the University of Bombay, India.

Mr. Schor has served as a member of our Board of Directors since November 2020.  Mr. Schor has served as  the President, Chief Executive Officer and Director of Adicet Bio, Inc. since September 2020.  He held the role of President and Chief Executive Officer at resTORbio since co-founding the company in 2016 until its merger with Adicet Bio in September 2020. Mr. Schor has led biotech companies across all stages, from formation and early stage discovery to a publicly traded multi-product company with significant big pharma partnerships. Prior to co-founding resTORbio, Mr. Schor led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals. Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital, where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor has led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA (co-led) and Cephalon (co-led). Mr. Schor holds a B.A. in Biology and an M.B.A. from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and is a Certified Public Accountant (CPA).

Dr. Su has served as a member of our Board of Directors since August 2023.  Dr. Su has been the Chief Executive Officer of Marengo Therapeutics and member of its Board of Directors since July 2021. Prior to joining Marengo, Dr. Su served as Senior Vice President and Global Head of the Oncology Business Franchise for Merck KGaA from 2019 to 2021 and concurrently as US Head of the Oncology Business Unit from 2020 to 2021. Dr. Su was Chief Medical Officer of EMD Serono from  2017 to 2019. Dr. Su also held leadership roles with increasing responsibility at Sanofi Oncology and GSK. Before his industry career, Dr. Su served on the faculty of Duke University Medical School, where he led early Oncology clinical studies focusing on mRNA-based and cell-based immunotherapy and then the University of Florida, where he was the director of the Cell and Gene Therapy program. Dr. Su received his Doctor of Medicine from Technical University of Dresden in Germany and his MBA from the University of Toronto in Canada.